A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Works by LoRusso, P M
Results: 3
1
2
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
- Published in:
- 2011
- By:
- Publication type:
- journal article
3
Targeting the epidermal growth factor receptor.
- Published in:
- 2004
- By:
- Publication type:
- journal article